In-person and virtual events just for HCPs

In-person and virtual events just for HCPs

View More Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

All Oncology News

OncLive News Network®

Insights MedNews Week OncChats OncLive News Network®OncLive TV Peer Exchange Podcasts Rapid Readouts

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Giants of Cancer Care

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Giants of Cancer Care CME/CE Scientific Interchanges State of the Science Summit / IPC National Fellows Forum Webinars

Partners Publications

Interactive Tools

Interactive Tools Sponsored

Biomarker Consortium Subscribe

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2024 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

OncLive SOSS

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Treatment of ALK- or ROS1-Mutated Non-Small Cell Lung Cancer

EP. 1: The Evolution of ALK/ROS1-Targeted TKIs

January 31st 2017

EP. 2: Crizotinib Resistance in ALK+ NSCLC

January 31st 2017

EP. 3: Ceritinib and Alectinib in Relapsed ALK+ NSCLC

January 31st 2017

EP. 4: Experience with Ceritinib for ALK+ NSCLC

January 31st 2017

EP. 5: Ceritinib Alternative Dosing for ALK+ NSCLC

January 31st 2017

EP. 6: Alectinib for Relapsed/Refractory ALK+ NSCLC

January 31st 2017

EP. 7: Choosing Second-Line Therapy for ALK+ NSCLC

January 31st 2017

EP. 8: Mutation Testing to Guide ALK TKI Selection in NSCLC

January 31st 2017

EP. 9: ALK Inhibitor Sequencing in NSCLC

January 31st 2017

EP. 10: ASCEND-4: Upfront Ceritinib in ALK-Rearranged NSCLC

January 31st 2017

<
1
2
>